Novartis said its anti-inflammatory drug Cosentyx eased the symptoms of a painful, lump-forming skin condition in two late-stage trials, putting the approved treatment on track to further shore up sales growth at the Swiss drugmaker.
In a statement on Saturday, the company said that the drug, already approved for conditions like psoriasis and arthritis, demonstrated rapid and sustained relief in trial participants suffering from hidradenitis suppurativa.
The company said the painful inflammatory skin disease, for which few treatments are available, affects about 1% of the population but is difficult to diagnose.Novartis will become more reliant on drug development as it plans to spin off its generics unit Sandoz, which makes low-cost copies of treatments that have lost patent protection.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
FDA OKs Daxxify, an anti-wrinkle injection and Botox competitorStudies showed the Daxxify drug can temporarily improve moderate to severe frown lines in adults for a median duration of about six months, according to the company. FOX13
Weiterlesen »
Rambutan for Skin Benefits Rival Retinoids| Well+GoodIt delivers the same anti-aging and pore-minimizing benefits as retinoids (sans the redness, flakiness, and irritation)
Weiterlesen »
Ciara's Zipper-Front Leather Jumpsuit Is a Total '90s VibeCiara promoted her new skin-care line, OAM Skin, in NYC wearing a black leather jumpsuit from her own brand LITA by Ciara, styled with Celine boots.
Weiterlesen »
Report: August data shows housing market returning to ‘more normalized conditions’Brokers added 9,914 new listings during August, a drop from the 11,805 added in July and the year-ago total of 11,437.
Weiterlesen »
Viral video shows homeless fighting in squalid conditions on San Francisco streetThere is a lot to unpack from the short but chaotic video, which has been viewed over 2.2 million times on Twitter.
Weiterlesen »